

Emilio J Laserna-Mendieta

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6721249/publications.pdf>

Version: 2024-02-01

27
papers

1,235
citations

535685

17
h-index

466096

32
g-index

35
all docs

35
docs citations

35
times ranked

1762
citing authors

#	ARTICLE	IF	CITATIONS
1	EoE CONNECT, the European Registry of Clinical, Environmental, and Genetic Determinants in Eosinophilic Esophagitis: rationale, design, and study protocol of a large-scale epidemiological study in Europe. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210742.	1.4	13
2	Accurate and timely diagnosis of Eosinophilic Esophagitis improves over time in Europe. An analysis of the EoE CONNECT Registry. <i>United European Gastroenterology Journal</i> , 2022, 10, 507-517.	1.6	19
3	Ranking microbiome variance in inflammatory bowel disease: a large longitudinal intercontinental study. <i>Gut</i> , 2021, 70, 499-510.	6.1	127
4	Esophageal microbiome in active eosinophilic esophagitis and changes induced by different therapies. <i>Scientific Reports</i> , 2021, 11, 7113.	1.6	27
5	Comparison of a new rapid method for determination of serum anti-adalimumab and anti-infliximab antibodies with two established ELISA kits. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 198, 114003.	1.4	9
6	Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. <i>Digestive and Liver Disease</i> , 2021, 53, 1479-1485.	0.4	30
7	Poor Sensitivity of Fecal Gluten Immunogenic Peptides and Serum Antibodies to Detect Duodenal Mucosal Damage in Celiac Disease Monitoring. <i>Nutrients</i> , 2021, 13, 98.	1.7	14
8	Letter: PPI in EoE â€“ more questions than answers. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 366-367.	1.9	0
9	Effects of anti-TNF-alpha therapy on hemoglobin levels and anemia in patients with inflammatory bowel disease. <i>Digestive and Liver Disease</i> , 2020, 52, 400-407.	0.4	9
10	Esophageal perforation in eosinophilic esophagitis: A systematic review on clinical presentation, management and outcomes. <i>Digestive and Liver Disease</i> , 2020, 52, 245-252.	0.4	25
11	Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 798-807.	1.9	72
12	Colonic microbiota is associated with inflammation and host epigenomic alterations in inflammatory bowel disease. <i>Nature Communications</i> , 2020, 11, 1512.	5.8	167
13	Piphillin predicts metagenomic composition and dynamics from DADA2-corrected 16S rDNA sequences. <i>BMC Genomics</i> , 2020, 21, 56.	1.2	54
14	Efficacy of Therapy for Eosinophilic Esophagitis in Real-World Practice. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 2903-2911.e4.	2.4	51
15	Genetic predictors of long-term response and trough levels of infliximab in crohn's disease. <i>Pharmacological Research</i> , 2019, 149, 104478.	3.1	17
16	Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1906-1914.	1.4	18
17	Systematic review with meta-analysis: the growing incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 1116-1125.	1.9	192
18	Faecal calprotectin in inflammatory bowel diseases: a review focused on meta-analyses and routine usage limitations. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 1295-1307.	1.4	27

#	ARTICLE	IF	CITATIONS
19	Determinants of Reduced Genetic Capacity for Butyrate Synthesis by the Gut Microbiome in Crohn's Disease and Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 204-216.	0.6	93
20	A comparison of the gut microbiome between long-term users and non-users of proton pump inhibitors. <i>Alimentary Pharmacology and Therapeutics</i> , 2016, 43, 974-984.	1.9	126
21	A multicentre analysis of four low-density lipoprotein cholesterol direct assays in samples with extreme high-density lipoprotein cholesterol concentrations. <i>Clinica Chimica Acta</i> , 2014, 430, 71-76.	0.5	2
22	A proposed reference change value for an IgA anti-tissue transglutaminase immunoassay to improve interpretation of serial results in celiac patients. <i>Clinica Chimica Acta</i> , 2013, 421, 12-16.	0.5	1
23	Comparison of the performance of the Brazilian equation for LDL-c estimation with other proposed formulae in a Spanish population. <i>Annals of Clinical Biochemistry</i> , 2013, 50, 501-502.	0.8	3
24	Biological variation and reference change values of common clinical chemistry and haematologic laboratory analytes in the elderly population. <i>Clinical Chemistry and Laboratory Medicine</i> , 2013, 51, 851-862.	1.4	45
25	Importancia de la selección de una especificación de calidad adecuada en la aplicación del modelo Seis-Sigma en el laboratorio clínico. <i>Revista Del Laboratorio Clínico</i> , 2012, 5, 170-176.	0.1	0
26	Extreme concentrations of high density lipoprotein cholesterol affect the calculation of low density lipoprotein cholesterol in the Friedewald formula and other proposed formulas. <i>Clinical Biochemistry</i> , 2011, 44, 1451-1456.	0.8	13
27	Proteomic Analysis of Phosphorylated Nuclear Proteins Underscores Novel Roles for Rapid Actions of Retinoic Acid in the Regulation of mRNA Splicing and Translation. <i>Molecular Endocrinology</i> , 2009, 23, 1799-1814.	3.7	19